PURPOSE: Observational studies describe high rates of errors in home oral chemotherapy use in children. In hospitals, proactive risk assessment methods help front-line health care workers develop error prevention strategies. Our objective was to engage parents of children with cancer in a multisite study using proactive risk assessment methods to identify how errors occur at home and propose risk reduction strategies. METHODS: We recruited parents from three outpatient pediatric oncology clinics in the northeast and southeast United States to participate in failure mode and effects analyses (FMEA). An FMEA is a systematic team-based proactive risk assessment approach in understanding ways a process can fail and develop prevention strategies. Steps included diagram the process, brainstorm and prioritize failure modes (places where things go wrong), and propose risk reduction strategies. We focused on home oral chemotherapy administration after a change in dose because prior studies identified this area as high risk. RESULTS: Parent teams consisted of four parents at two of the sites and 10 at the third. Parents developed a 13-step process map, with two to 19 failure modes per step. The highest priority failure modes included miscommunication when receiving instructions from the clinician (caused by conflicting instructions or parent lapses) and unsafe chemotherapy handling at home. Recommended risk assessment strategies included novel uses of technology to improve parent access to information, clinicians, and other parents while at home. CONCLUSION: Parents of pediatric oncology patients readily participated in a proactive risk assessment method, identifying processes that pose a risk for medication errors involving home oral chemotherapy.
PURPOSE: Observational studies describe high rates of errors in home oral chemotherapy use in children. In hospitals, proactive risk assessment methods help front-line health care workers develop error prevention strategies. Our objective was to engage parents of children with cancer in a multisite study using proactive risk assessment methods to identify how errors occur at home and propose risk reduction strategies. METHODS: We recruited parents from three outpatient pediatric oncology clinics in the northeast and southeast United States to participate in failure mode and effects analyses (FMEA). An FMEA is a systematic team-based proactive risk assessment approach in understanding ways a process can fail and develop prevention strategies. Steps included diagram the process, brainstorm and prioritize failure modes (places where things go wrong), and propose risk reduction strategies. We focused on home oral chemotherapy administration after a change in dose because prior studies identified this area as high risk. RESULTS: Parent teams consisted of four parents at two of the sites and 10 at the third. Parents developed a 13-step process map, with two to 19 failure modes per step. The highest priority failure modes included miscommunication when receiving instructions from the clinician (caused by conflicting instructions or parent lapses) and unsafe chemotherapy handling at home. Recommended risk assessment strategies included novel uses of technology to improve parent access to information, clinicians, and other parents while at home. CONCLUSION: Parents of pediatric oncology patients readily participated in a proactive risk assessment method, identifying processes that pose a risk for medication errors involving home oral chemotherapy.
Authors: David Phillip Alldred; Claire Standage; Olivia Fletcher; Imogen Savage; James Carpenter; Nick Barber; David Kenneth Raynor Journal: BMJ Qual Saf Date: 2011-02-07 Impact factor: 7.035
Authors: Kathleen E Walsh; Kathleen M Mazor; Christopher J Stille; Irma Torres; Joann L Wagner; Juliet Moretti; Kevin Chysna; Christy D Stine; G Naheed Usmani; Jerry H Gurwitz Journal: Arch Dis Child Date: 2011-03-27 Impact factor: 3.791
Authors: Saul N Weingart; Tejal K Gandhi; Andrew C Seger; Diane L Seger; Joshua Borus; Elisabeth Burdick; Lucian L Leape; David W Bates Journal: Arch Intern Med Date: 2005-01-24
Authors: Tejal K Gandhi; Sylvia B Bartel; Lawrence N Shulman; Deborah Verrier; Elisabeth Burdick; Angela Cleary; Jeffrey M Rothschild; Lucian L Leape; David W Bates Journal: Cancer Date: 2005-12-01 Impact factor: 6.860
Authors: Beverly B Green; Andrea J Cook; James D Ralston; Paul A Fishman; Sheryl L Catz; James Carlson; David Carrell; Lynda Tyll; Eric B Larson; Robert S Thompson Journal: JAMA Date: 2008-06-25 Impact factor: 56.272
Authors: James D Ralston; Irl B Hirsch; James Hoath; Mary Mullen; Allen Cheadle; Harold I Goldberg Journal: Diabetes Care Date: 2008-11-18 Impact factor: 17.152
Authors: Sarabeth Broder-Fingert; Sarah Qin; Julia Goupil; Jessica Rosenberg; Marilyn Augustyn; Nate Blum; Amanda Bennett; Carol Weitzman; James P Guevara; Ada Fenick; Michael Silverstein; Emily Feinberg Journal: Autism Date: 2018-11-08
Authors: Kathleen E Walsh; Colleen Biggins; Deb Blasko; Steven M Christiansen; Shira H Fischer; Christopher Keuker; Robert Klugman; Kathleen M Mazor Journal: J Oncol Pract Date: 2014-10-21 Impact factor: 3.840
Authors: James M Hoffman; Nicholas J Keeling; Christopher B Forrest; Heather L Tubbs-Cooley; Erin Moore; Emily Oehler; Stephanie Wilson; Elisabeth Schainker; Kathleen E Walsh Journal: Pediatrics Date: 2019-02 Impact factor: 7.124
Authors: Kathleen E Walsh; Sarah L Cutrona; Patricia L Kavanagh; Lori E Crosby; Chris Malone; Katie Lobner; David G Bundy Journal: Pediatrics Date: 2014-11-17 Impact factor: 7.124
Authors: Kathleen E Walsh; Douglas W Roblin; Saul N Weingart; Kathleen E Houlahan; Barbara Degar; Amy Billett; Christopher Keuker; Colleen Biggins; Justin Li; Karen Wasilewski; Kathleen M Mazor Journal: Pediatrics Date: 2013-04-29 Impact factor: 7.124
Authors: Valentina Lichtner; Melissa Baysari; Peter Gates; Luciano Dalla-Pozza; Johanna I Westbrook Journal: Eur J Cancer Care (Engl) Date: 2019-08-22 Impact factor: 2.520